NCT04584580

D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

evaluation of the efficacy and safety of D-dimer adjusted heparin versus therapeutic dose heparin in patients with COVID-19 Pneumonia.

Detailed description

The following will be done for enrolled patients: 1. Data collection: name, age, sex, special habits of medical importance (i.e. smoking, drug abuse), comorbid conditions. 2. Clinical examination Vital data Local chest examination 3. Measurement of oxygen saturation using pulse oximeter 4. Laboratory investigations: Complete blood count with differential count Liver and kidney functions D-dimer level Coagulation profile 5. Radiology work up ( Chest X-ray-High resolution computed tomography of the chest- computed tomography of the chest with pulmonary angiography as needed) 6. Sepsis-induced coagulopathy score (SIC score) 7. Sequential organ failure score (SOFA score) 8. Patients will receive treatment according to the hospital guidelines for different disease stratification severity

Conditions

• Coronavirus Disease (COVID)19

Interventions

Type	Name	Description
DRUG	low-molecular-weight heparin	low-molecular-weight heparin administered via subcutaneous injection

Timeline

• Start date: 2020-08-01
• Primary completion: 2020-10-31
• Completion: 2020-12-31
• First posted: 2020-10-14
• Last updated: 2020-10-14

Locations

1 site across 1 country: Egypt